<DOC>
	<DOCNO>NCT00004040</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Biological therapy interferon alfa-2b use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase II trial study effectiveness rituximab interferon alfa-2b treating patient chronic lymphocytic leukemia multiple myeloma remission .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Biological Therapy Treating Patients With Chronic Lymphocytic Leukemia Multiple Myeloma Remission After Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity rituximab interferon alfa-2b maintenance therapy patient chronic lymphocytic leukemia multiple myeloma remission chemotherapy . II . Determine progression free survival , failure free survival , overall survival patient time chemotherapy discontinuation completion maintenance therapy . III . Compare survival rate patient similar patient treat publish study . IV . Determine quality life patient regimens . OUTLINE : Patients enter one two treatment arm : Arm I : Patients receive rituximab IV day 1 , 8 , 15 , 22 course 1 , month 11 month disease progression . Arm II : Patients receive subcutaneous interferon alfa-2b every day three time per week 12 month . Quality life assess monthly therapy . Patients follow every 3 month 1 year , annually 5 year . PROJECTED ACCRUAL : A total 60-80 patient ( 30-40 per disease type ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Bcell chronic lymphocytic leukemia multiple myeloma remission previously treat chemotherapy without disease progression PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Lymphocyte count le 10,000/mm3 Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No active infection concurrent lifethreatening disease Medical condition satisfactory treatment chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>